Palvella Therapeutics, Inc.

US$175.92As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:PVLAHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (63.39%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM 120.34%
Mkt cap US$2.572B
ROIC (31.60%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$170
(3.34%)
(67.52%)
Hold 0|2|12|5|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
3.07
3.08
3.45
3.69
(0.96%)
(5.40%)
9.81%
22.99%
Revenue$M
130.6
132.8
136.5
140.8
0.79%
4.46%
4.85%
10.83%
Peers (US$2.572B)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.387
0.119
0.119
EBIT/Intx
1.346
4.990
4.626
Own earn%
(101.24)
130.25
98.84
Sh yield%
33.53
52.82
49.58
Owners
Insiders/Inst%
3.48
37.23
Short interest%
2.29
SBC / revenue%
3.85
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
16–21
$1 testx
—
Incr. ROIC%
3